Enobia Pharma Announces the Appointment of Dr. Hal Landy as VP Medical Affairs, Chief Medical Officer
June 18, 2007
Montreal, Quebec, CANADA – June 18, 2007 – Enobia Pharma, announced today that it has appointed Hal Landy, MD as the Company’s VP Medical Affairs & Chief Medical Officer.
“With our pediatric focus and as we prepare to bring our first compound into the clinic, we welcome the leadership and experience in enzyme replacement therapies, pediatric disorders and orphan products that Dr. Landy brings to the Company”, stated Robert Heft, PhD, President and CEO of Enobia Pharma.
“Enobia’s technology has the potential to greatly alleviate the suffering associated with several serious bone related disorders and the Company has been successful in attracting the commitment and confidence of a strong investor base. I look forward to being part of this team,” Dr. Landy stated.
Dr. Landy, has 15 years of senior management experience in the biopharmaceutical industry. From 2003 through 2007, Dr. Landy served as Vice-President Clinical Development with Repligen Corporation (Nasdaq: RGEN, Waltham, Massachusetts) where he oversaw programs in autism, neuropsychiatric indications, immunological diseases, gastroenterology and imaging.
Prior to joining Repligen, Dr. Landy was Vice-President Clinical Research of Genzyme. (Nasdaq: GENZ, Cambridge, Massachusetts), a company that was originally focused on the development of enzyme replacement therapies. He was the medical lead on an extensive and ultimately successful program in Pompé disease. Before that, Dr. Landy served in various capacities at Serono, both in the US and Geneva, where he oversaw successful programs in growth-related disorders and worked in AIDS-wasting and metabolism.
Dr. Landy received his MD from the College of Physicians and Surgeons, Columbia University in 1981. He subsequently trained in Pediatrics and Adolescent Medicine at Massachusetts General Hospital and Children’s Hospital, Boston, and was Board certified in Pediatrics in 1987 and in Pediatric Endocrinology in 1989. He was Assistant in Medicine at Children’s Hospital, Boston and Instructor in Pediatrics, Harvard Medical School from 1989 – 1996.
About Enobia Pharma
Enobia Pharma is a Montreal based, privately held company founded in 1997. The Company is developing Enzyme Replacement Therapeutics and other compounds for the treatment of serious bone diseases. The current investors of Enobia Pharma are Desjardins Capital de Risque, Fonds de solidarité FTQ, Lothian Partners and T2C2/Bio.
For additional information on Enobia Pharma, please contact:
Mr. Luc Cournoyer, VP Finance
Enobia Pharma
2901 Rachel Street East, Suite 23, Montreal, Quebec, CANADA.H1W 4A4
(514) 596-2901 extension # 223
Email: luc.cournoyer@enobia.com
Back